SPN-820: Rapid-Acting Antidepressant Shows Promising Phase 2 ResultsByHeidi Anne Duerr, MPH,Himanshu Upadhyaya, MBBS, MBADecember 11th 2024Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.